MeiraGTx has secured an investment of up to $400 million from Oberland Capital to help get its late-stage gene therapies | As ...

Diagnostics specialist Beckman Coulter has expanded its portfolio of Alzheimer’s disease diagnostics by earning a ...

Clinical-stage biotech Kalohexis is preparing for a public listing to support its obesity and cancer cachexia treatments. | ...

Boehringer Ingelheim has landed an exclusive license to Prime Vector Technologies’ (PVT) viral vector platform for developing ...

Biocytogen and Whitehawk Therapeutics are joining forces to develop bispecific antibody-drug conjugates (ADCs) using ...

As U.S. lawmakers continue to scrutinize the consequences of China’s expanding role in biotech innovation, industry insiders ...

Women in England are set to gain new, taxpayer-funded tests for endometriosis after NICE recommended them for regular use. | ...

As Novo Nordisk looks for new ways to broaden its semaglutide GLP-1 franchise, the Danish drugmaker has signed a new deal ...

Phase 3 trials of Kailera Therapeutics’ oral GLP-1 prospect have hit their primary endpoints, positioning the biotech’s ...

Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials. While the Bay Area biotech has yet to set ...

Novartis is pushing deeper into antibody-drug conjugate (ADC) development, paying $1.1 billion upfront to buy Myricx Bio for a pipeline based on a novel payload. Switzerland’s Novartis largely stayed ...

A month after Genentech confirmed the restructuring of its early development group, the Roche subsidiary has now disclosed ...